Noqturina (Desmopressin)

Desmopressin is a synthetic analogue of the natural hormone vasopressin. It selectively activates V2 receptors in the kidney’s collecting ducts, which triggers a cascade that inserts water‑channel proteins (aquaporin‑2) into the cell membrane, allowing more water to be reabsorbed and urine to become more concentrated. The same receptor activation also stimulates release of clotting factors VIII and von Willebrand factor from endothelial cells.

The dose of Noqturina is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function and response to therapy. Healthcare professionals determine the appropriate strength, frequency and duration of treatment, and patients should follow the prescriber’s instructions exactly.

Safety data for desmopressin in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To request Noqturina, visit the product page on gnhindia.com, enter the desired quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Desmopressin is a selective V2‑receptor agonist, offering a longer duration of action and fewer vasoconstrictive effects compared with older vasopressin preparations. It is generally preferred for chronic management of central diabetes insipidus and for its haemostatic benefits in bleeding disorders, whereas non‑selective analogues may cause more cardiovascular side effects.

Noqturina should be stored at ambient temperature, below 25 °C. Keep the tablets in their original packaging to protect them from moisture and light, and store them out of reach of children.

Noqturina is supplied as a sublingual tablet. The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing whole. Patients should avoid eating or drinking for a few minutes after administration to ensure optimal absorption.

The most serious risks include hyponatraemia, which can lead to seizures, cerebral oedema, or water intoxication. Patients should be monitored for signs of low sodium, such as headache, nausea, confusion, or weakness, and fluid intake should be managed carefully.

Noqturina is contraindicated in patients with known hypersensitivity to desmopressin or any excipients, in those with uncontrolled hyponatraemia, and in individuals with severe renal impairment where water balance cannot be safely managed. Clinicians should also exercise caution in patients taking other medications that predispose to low sodium levels.